Institute for Molecular Medicine

CompanyUnited States

Institute for Molecular Medicine develops one asset, in phase 1 (AV-1980R in Alzheimer's disease). Mostly vaccine acting on MAPT and proteostasis; based in the United States.

Assets
1
Furthest
Phase 1
Grants
3
Trials
0
Signals
5

Pipeline

1

  • AV-1980R

    Investigational preventive vaccine inducing immune responses against pathological tau protein

    Phase 1VaccineMAPTProteostasisAlzheimer's disease

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms2
  • People5
  • Signals6
  • Integrity notices3
  • Similar companies6

Updated 7 Oct 2026 · 5 sources

Intelligence